[{"address1": "12790 El Camino Real", "address2": "Suite 200", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "760 593 4832", "website": "https://ventyxbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in Phase 2a trial for patients with early Parkinson's disease and is in Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California.", "fullTimeEmployees": 81, "companyOfficers": [{"maxAge": 1, "name": "Dr. Sheila K. Gujrathi M.D.", "age": 54, "title": "Executive Chairperson", "yearBorn": 1970, "fiscalYear": 2024, "totalPay": 125000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Raju S. Mohan Ph.D.", "age": 66, "title": "Founder, CEO, President & Director", "yearBorn": 1958, "fiscalYear": 2024, "totalPay": 979215, "exercisedValue": 0, "unexercisedValue": 5922}, {"maxAge": 1, "name": "Mr. Matthew Richard Moore", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 612510, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mark S. Forman M.D., Ph.D.", "age": 60, "title": "Chief Medical Officer", "yearBorn": 1964, "fiscalYear": 2024, "totalPay": 380965, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Roy M. Gonzales CPA, M.B.A.", "age": 48, "title": "Senior VP of Finance and Principal Financial & Accounting Officer", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John M. Nuss Ph.D.", "age": 65, "title": "Chief Scientific Officer", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 630635, "exercisedValue": 0, "unexercisedValue": 451580}, {"maxAge": 1, "name": "Ms. Snehal  Naik Ph.D.", "title": "Senior VP of Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kathy  Ogilvie Ph.D.", "title": "Senior VP of Translational & Nonclinical Research", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Rosa  Ferrao", "title": "Senior VP of Regulatory Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 10, "governanceEpochDate": 1754006400, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 3.0, "open": 3.03, "dayLow": 2.83, "dayHigh": 3.0494, "regularMarketPreviousClose": 3.0, "regularMarketOpen": 3.03, "regularMarketDayLow": 2.83, "regularMarketDayHigh": 3.0494, "payoutRatio": 0.0, "beta": 0.968, "forwardPE": -1.3162789, "volume": 702548, "regularMarketVolume": 702548, "averageVolume": 1634848, "averageVolume10days": 810900, "averageDailyVolume10Day": 810900, "bid": 2.16, "ask": 3.66, "bidSize": 2, "askSize": 2, "marketCap": 201803040, "fiftyTwoWeekLow": 0.783, "fiftyTwoWeekHigh": 3.39, "fiftyDayAverage": 2.6178, "twoHundredDayAverage": 1.97924, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 3139106, "profitMargins": 0.0, "floatShares": 55695518, "sharesOutstanding": 71308496, "sharesShort": 4752363, "sharesShortPriorMonth": 5286349, "sharesShortPreviousMonthDate": 1751241600, "dateShortInterest": 1753920000, "sharesPercentSharesOut": 0.066700004, "heldPercentInsiders": 0.041100003, "heldPercentInstitutions": 0.68253, "shortRatio": 3.76, "shortPercentOfFloat": 0.0709, "impliedSharesOutstanding": 71308496, "bookValue": 2.939, "priceToBook": 0.96291256, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -119027000, "trailingEps": -1.66, "forwardEps": -2.15, "enterpriseToEbitda": -0.024, "52WeekChange": 0.43654823, "SandP52WeekChange": 0.15005577, "quoteType": "EQUITY", "currentPrice": 2.83, "targetHighPrice": 21.0, "targetLowPrice": 2.0, "targetMeanPrice": 11.5, "targetMedianPrice": 11.5, "recommendationMean": 1.625, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 208959008, "totalCashPerShare": 2.93, "ebitda": -130108000, "totalDebt": 10295000, "quickRatio": 18.307, "currentRatio": 19.123, "debtToEquity": 4.917, "returnOnAssets": -0.3023, "returnOnEquity": -0.48564997, "freeCashflow": -59710000, "operatingCashflow": -105705000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "VTYX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Ventyx Biosciences, Inc.", "longName": "Ventyx Biosciences, Inc.", "corporateActions": [], "postMarketChangePercent": 1.72085, "postMarketPrice": 2.8787, "postMarketChange": 0.0487001, "regularMarketChange": -0.17, "regularMarketDayRange": "2.83 - 3.0494", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1634848, "fiftyTwoWeekLowChange": 2.047, "fiftyTwoWeekLowChangePercent": 2.6143038, "fiftyTwoWeekRange": "0.783 - 3.39", "fiftyTwoWeekHighChange": -0.5600002, "fiftyTwoWeekHighChangePercent": -0.16519178, "fiftyTwoWeekChangePercent": 43.654823, "earningsTimestampStart": 1762459200, "earningsTimestampEnd": 1762459200, "earningsCallTimestampStart": 1715286600, "earningsCallTimestampEnd": 1715286600, "isEarningsDateEstimate": true, "hasPrePostMarketData": true, "epsTrailingTwelveMonths": -1.66, "epsForward": -2.15, "epsCurrentYear": -1.68429, "priceEpsCurrentYear": -1.6802331, "fiftyDayAverageChange": 0.21219993, "fiftyDayAverageChangePercent": 0.0810604, "twoHundredDayAverageChange": 0.85076, "twoHundredDayAverageChangePercent": 0.42984176, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-10-21", "averageAnalystRating": "1.6 - Buy", "cryptoTradeable": false, "firstTradeDateMilliseconds": 1634823000000, "postMarketTime": 1755298733, "regularMarketTime": 1755288000, "exchange": "NMS", "messageBoardId": "finmb_672535556", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "market": "us_market", "marketState": "CLOSED", "gmtOffSetMilliseconds": -14400000, "esgPopulated": false, "regularMarketChangePercent": -5.66667, "regularMarketPrice": 2.83, "displayName": "Ventyx Biosciences", "trailingPegRatio": null, "__fetch_time": "2025-08-16"}]